Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy - Top-Institutions - MDSpire

Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy

  • By

  • Liangkui Luo

  • Kaikai Huang

  • Yanbin Pang

  • May 25, 2026

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    National Institutes of Health Clinical Center – NHLBI Hematology Branch
    National Institutes of Health Clinical Center – NHLBI Hematology Branch

    Bethesda, Maryland

    Key Differentiators

    • Hematology
    • Bone Marrow Failure

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Mass General Brigham Cancer Institute
    Mass General Brigham Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy

  • by Liangkui Luo, Kaikai Huang, Yanbin Pang

  • May 25, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 13, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Stuart Orkin Awarded Breakthrough Prize in Life Sciences

Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor, Harvard Medical School and Investigator, Howard Hughes Medical Institute, has been honored with The Breakthrough Prize in Life Sciences for discovering how the body turns off fetal hemoglobin after birth, a finding that led to a new treatment strategy for sickle cell disease. Dr. Orkin shares the prize with SweeLay Thein, Investigator at the National Institutes of Health (NIH).

  • by

  • April 19, 2026

  • 6 min